European Commission grants authorisation for Cinqaero
Teva announced today that the European Commission has granted marketing authorisation for Cinqaero (reslizumab) following an efficacy probe.
The drug, used for adults with severe eosinophilic asthma, has been approved in the 28 countries of the EU as well as in Norway, Liechtenstein and Iceland.
The approval by the commission was based on a review of the drug’s efficacy and safety data from Teva’s global development programme.
Rob Koremans, CEO of Teva Global Specialty Medicines, said: “Severe asthma is a significant health issue in Europe and around the world—and for patients living with a severe form of the condition marked by elevated eosinophils—finding an effective treatment option may be a challenge.”
Cinqaero is expected to become commercially available to patients in Europe, by prescription, within the coming months.
